Table 1.
Pharmacokinetic Parameters of Pomalidomide in the Reported Patient With HCO Dialysis
| Parameter | Our Patient | Reference Values | |
|---|---|---|---|
| Healthy Person | Multiple Myeloma | ||
| Dose, mg/d | 2a | 2 | 4 |
| Pharmacokinetic parameters | |||
| CLR, mL/min | 3 | 4 | 3 |
| CLNR, mL/min | 47 | 172 | 127 |
| CLTot/F, mL/min | 50 | 176b | 130 |
| Vss/F, L | 132 | — | 141 |
| t1/2 off dialysis, h | 14.3 | 8.9 | 7.5 |
| AUC24h, μg·h/L | 475 on dialysis; 574 off dialysis | 189 ± 52 | 513b |
| Hemodialysis elimination | |||
| E, % | 37–65 | — | — |
| CLDial predicted, mL/min | 155–181 | — | — |
| CLDial observed, mL/min | 187–663 | — | — |
| t1/2 on dialysis, h | 3.5 | — | — |
Abbreviations and definitions (further information in Item S1): AUC24h, area under the curve calculated by numerical integration over 24 h; CLDial observed, observed dialytic clearance, or difference between concentration entering the dialyzer vs that leaving it, multiplied by blood flow, divided by concentration entering the dialyzer; CLDial predicted, predicted dialytic clearance, or product of blood flow, fraction unbound, and blood-plasma concentration ratio; CLNR, nonrenal clearance or CLTot/F multiplied by hepatic extraction ratio; CLR, renal clearance; CLTot, total clearance; E, extraction coefficient, or observed dialytic clearance divided by blood flow; F, bioavailability; t1/2, half-life; VSS, sum of central and peripheral volumes of distribution.
At the end of HCO dialysis.
Based on the relation AUC:Dose/(CL/F).